{
    "medicine_id": "a2d45176cd3ab32ba216ee500292a78ee3c2504c",
    "platform_id": "DB09312",
    "metadata": {
        "name": "Atgam 50 mg Solution",
        "composition": "50 mg Antilymphocyte immunoglobulin horse",
        "clinical_particulars": {
            "therapeutic_indications": "For prevention of renal transplant rejection and for the treatment of aplastic anemia",
            "contraindications": {
                "disease": "The most commonly reported adverse reactions occurring in greater than 10 of patients are pyrexia chills rash thrombocytopenia leukopenia and arthralgia",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB06643",
                        "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00005",
                        "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00008",
                        "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa 2a is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00011",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa n1 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00018",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa n3 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00022",
                        "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa 2b is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00026",
                        "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00033",
                        "description": "The risk or severity of adverse effects can be increased when Interferon gamma 1b is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00034",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa 2a Recombinant is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00041",
                        "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00051",
                        "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00056",
                        "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00059",
                        "description": "The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00068",
                        "description": "The risk or severity of adverse effects can be increased when Interferon beta 1b is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00069",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfacon 1 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00073",
                        "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00074",
                        "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00075",
                        "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00078",
                        "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00081",
                        "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00087",
                        "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00092",
                        "description": "The risk or severity of adverse effects can be increased when Alefacept is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00095",
                        "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00098",
                        "description": "The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin rabbit is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00105",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa 2b is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00111",
                        "description": "The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00120",
                        "description": "The risk or severity of adverse effects can be increased when Phenylalanine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00180",
                        "description": "The risk or severity of adverse effects can be increased when Flunisolide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The risk or severity of adverse effects can be increased when Bortezomib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00242",
                        "description": "The risk or severity of adverse effects can be increased when Cladribine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00262",
                        "description": "The risk or severity of adverse effects can be increased when Carmustine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00276",
                        "description": "The risk or severity of adverse effects can be increased when Amsacrine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00290",
                        "description": "The risk or severity of adverse effects can be increased when Bleomycin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00291",
                        "description": "The risk or severity of adverse effects can be increased when Chlorambucil is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00293",
                        "description": "The risk or severity of adverse effects can be increased when Raltitrexed is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00305",
                        "description": "The risk or severity of adverse effects can be increased when Mitomycin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00307",
                        "description": "The risk or severity of adverse effects can be increased when Bexarotene is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The risk or severity of adverse effects can be increased when Vindesine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00322",
                        "description": "The risk or severity of adverse effects can be increased when Floxuridine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "The risk or severity of adverse effects can be increased when Indomethacin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00352",
                        "description": "The risk or severity of adverse effects can be increased when Tioguanine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The risk or severity of adverse effects can be increased when Vinorelbine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00380",
                        "description": "The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00394",
                        "description": "The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The risk or severity of adverse effects can be increased when Sorafenib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00428",
                        "description": "The risk or severity of adverse effects can be increased when Streptozocin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00432",
                        "description": "The risk or severity of adverse effects can be increased when Trifluridine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00441",
                        "description": "The risk or severity of adverse effects can be increased when Gemcitabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00443",
                        "description": "The risk or severity of adverse effects can be increased when Betamethasone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00444",
                        "description": "The risk or severity of adverse effects can be increased when Teniposide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00445",
                        "description": "The risk or severity of adverse effects can be increased when Epirubicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00446",
                        "description": "The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00480",
                        "description": "The risk or severity of adverse effects can be increased when Lenalidomide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00488",
                        "description": "The risk or severity of adverse effects can be increased when Altretamine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00495",
                        "description": "The risk or severity of adverse effects can be increased when Zidovudine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00515",
                        "description": "The risk or severity of adverse effects can be increased when Cisplatin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00526",
                        "description": "The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00531",
                        "description": "The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of adverse effects can be increased when Vincristine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00544",
                        "description": "The risk or severity of adverse effects can be increased when Fluorouracil is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00550",
                        "description": "The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00552",
                        "description": "The risk or severity of adverse effects can be increased when Pentostatin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00563",
                        "description": "The risk or severity of adverse effects can be increased when Methotrexate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00564",
                        "description": "The risk or severity of adverse effects can be increased when Carbamazepine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The risk or severity of adverse effects can be increased when Vinblastine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00588",
                        "description": "The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00591",
                        "description": "The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00601",
                        "description": "The risk or severity of adverse effects can be increased when Linezolid is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "The risk or severity of adverse effects can be increased when Imatinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00620",
                        "description": "The risk or severity of adverse effects can be increased when Triamcinolone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00631",
                        "description": "The risk or severity of adverse effects can be increased when Clofarabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00635",
                        "description": "The risk or severity of adverse effects can be increased when Prednisone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00642",
                        "description": "The risk or severity of adverse effects can be increased when Pemetrexed is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00687",
                        "description": "The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00688",
                        "description": "The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00694",
                        "description": "The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00755",
                        "description": "The risk or severity of adverse effects can be increased when Tretinoin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00762",
                        "description": "The risk or severity of adverse effects can be increased when Irinotecan is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00763",
                        "description": "The risk or severity of adverse effects can be increased when Methimazole is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00773",
                        "description": "The risk or severity of adverse effects can be increased when Etoposide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00795",
                        "description": "The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00851",
                        "description": "The risk or severity of adverse effects can be increased when Dacarbazine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00853",
                        "description": "The risk or severity of adverse effects can be increased when Temozolomide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00859",
                        "description": "The risk or severity of adverse effects can be increased when Penicillamine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00860",
                        "description": "The risk or severity of adverse effects can be increased when Prednisolone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00877",
                        "description": "The risk or severity of adverse effects can be increased when Sirolimus is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00888",
                        "description": "The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00928",
                        "description": "The risk or severity of adverse effects can be increased when Azacitidine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00958",
                        "description": "The risk or severity of adverse effects can be increased when Carboplatin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00959",
                        "description": "The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00970",
                        "description": "The risk or severity of adverse effects can be increased when Dactinomycin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00987",
                        "description": "The risk or severity of adverse effects can be increased when Cytarabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00993",
                        "description": "The risk or severity of adverse effects can be increased when Azathioprine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00997",
                        "description": "The risk or severity of adverse effects can be increased when Doxorubicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01005",
                        "description": "The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01008",
                        "description": "The risk or severity of adverse effects can be increased when Busulfan is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01024",
                        "description": "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01030",
                        "description": "The risk or severity of adverse effects can be increased when Topotecan is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01033",
                        "description": "The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01041",
                        "description": "The risk or severity of adverse effects can be increased when Thalidomide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01042",
                        "description": "The risk or severity of adverse effects can be increased when Melphalan is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01073",
                        "description": "The risk or severity of adverse effects can be increased when Fludarabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01099",
                        "description": "The risk or severity of adverse effects can be increased when Flucytosine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01101",
                        "description": "The risk or severity of adverse effects can be increased when Capecitabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01108",
                        "description": "The risk or severity of adverse effects can be increased when Trilostane is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01168",
                        "description": "The risk or severity of adverse effects can be increased when Procarbazine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01169",
                        "description": "The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01177",
                        "description": "The risk or severity of adverse effects can be increased when Idarubicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01181",
                        "description": "The risk or severity of adverse effects can be increased when Ifosfamide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01196",
                        "description": "The risk or severity of adverse effects can be increased when Estramustine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01204",
                        "description": "The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01206",
                        "description": "The risk or severity of adverse effects can be increased when Lomustine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01222",
                        "description": "The risk or severity of adverse effects can be increased when Budesonide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01234",
                        "description": "The risk or severity of adverse effects can be increased when Dexamethasone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The risk or severity of adverse effects can be increased when Dasatinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01257",
                        "description": "The risk or severity of adverse effects can be increased when Eculizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01262",
                        "description": "The risk or severity of adverse effects can be increased when Decitabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The risk or severity of adverse effects can be increased when Sunitinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01280",
                        "description": "The risk or severity of adverse effects can be increased when Nelarabine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01281",
                        "description": "The risk or severity of adverse effects can be increased when Abatacept is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01285",
                        "description": "The risk or severity of adverse effects can be increased when Corticotropin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01380",
                        "description": "The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01384",
                        "description": "The risk or severity of adverse effects can be increased when Paramethasone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The risk or severity of adverse effects can be increased when Colchicine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01410",
                        "description": "The risk or severity of adverse effects can be increased when Ciclesonide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01423",
                        "description": "The risk or severity of adverse effects can be increased when Stepronin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01590",
                        "description": "The risk or severity of adverse effects can be increased when Everolimus is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01611",
                        "description": "The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01816",
                        "description": "The risk or severity of adverse effects can be increased when Castanospermine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB02546",
                        "description": "The risk or severity of adverse effects can be increased when Vorinostat is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB02806",
                        "description": "The risk or severity of adverse effects can be increased when 2 Methoxyethanol is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB03523",
                        "description": "The risk or severity of adverse effects can be increased when Brequinar is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04572",
                        "description": "The risk or severity of adverse effects can be increased when Thiotepa is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04630",
                        "description": "The risk or severity of adverse effects can be increased when Aldosterone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04845",
                        "description": "The risk or severity of adverse effects can be increased when Ixabepilone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The risk or severity of adverse effects can be increased when Nilotinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04951",
                        "description": "The risk or severity of adverse effects can be increased when Pirfenidone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04956",
                        "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05015",
                        "description": "The risk or severity of adverse effects can be increased when Belinostat is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05109",
                        "description": "The risk or severity of adverse effects can be increased when Trabectedin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05258",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05259",
                        "description": "The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05260",
                        "description": "The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05459",
                        "description": "The risk or severity of adverse effects can be increased when Briakinumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05472",
                        "description": "The risk or severity of adverse effects can be increased when Human interferon omega 1 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05676",
                        "description": "The risk or severity of adverse effects can be increased when Apremilast is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06168",
                        "description": "The risk or severity of adverse effects can be increased when Canakinumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06273",
                        "description": "The risk or severity of adverse effects can be increased when Tocilizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06287",
                        "description": "The risk or severity of adverse effects can be increased when Temsirolimus is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06372",
                        "description": "The risk or severity of adverse effects can be increased when Rilonacept is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The risk or severity of adverse effects can be increased when Pazopanib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The risk or severity of adverse effects can be increased when Panobinostat is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06612",
                        "description": "The risk or severity of adverse effects can be increased when Mepolizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06616",
                        "description": "The risk or severity of adverse effects can be increased when Bosutinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06662",
                        "description": "The risk or severity of adverse effects can be increased when Abetimus is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06674",
                        "description": "The risk or severity of adverse effects can be increased when Golimumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06681",
                        "description": "The risk or severity of adverse effects can be increased when Belatacept is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06769",
                        "description": "The risk or severity of adverse effects can be increased when Bendamustine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06772",
                        "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06813",
                        "description": "The risk or severity of adverse effects can be increased when Pralatrexate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08059",
                        "description": "The risk or severity of adverse effects can be increased when Wortmannin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08871",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08877",
                        "description": "The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08879",
                        "description": "The risk or severity of adverse effects can be increased when Belimumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08880",
                        "description": "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08889",
                        "description": "The risk or severity of adverse effects can be increased when Carfilzomib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08901",
                        "description": "The risk or severity of adverse effects can be increased when Ponatinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08904",
                        "description": "The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08906",
                        "description": "The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08908",
                        "description": "The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08935",
                        "description": "The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08970",
                        "description": "The risk or severity of adverse effects can be increased when Fluprednidene is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09029",
                        "description": "The risk or severity of adverse effects can be increased when Secukinumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09033",
                        "description": "The risk or severity of adverse effects can be increased when Vedolizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09036",
                        "description": "The risk or severity of adverse effects can be increased when Siltuximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09052",
                        "description": "The risk or severity of adverse effects can be increased when Blinatumomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09053",
                        "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09054",
                        "description": "The risk or severity of adverse effects can be increased when Idelalisib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09073",
                        "description": "The risk or severity of adverse effects can be increased when Palbociclib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09074",
                        "description": "The risk or severity of adverse effects can be increased when Olaparib is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09077",
                        "description": "The risk or severity of adverse effects can be increased when Dinutuximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09082",
                        "description": "The risk or severity of adverse effects can be increased when Vilanterol is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09091",
                        "description": "The risk or severity of adverse effects can be increased when Tixocortol is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09122",
                        "description": "The risk or severity of adverse effects can be increased when Peginterferon beta 1a is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09378",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fluprednisolone"
                    },
                    {
                        "drugbank-id": "DB09383",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Meprednisone"
                    },
                    {
                        "drugbank-id": "DB11466",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tepoxalin"
                    },
                    {
                        "drugbank-id": "DB11487",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dexamethasone isonicotinate"
                    },
                    {
                        "drugbank-id": "DB11529",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Melengestrol"
                    },
                    {
                        "drugbank-id": "DB11569",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ixekizumab"
                    },
                    {
                        "drugbank-id": "DB11580",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ravulizumab"
                    },
                    {
                        "drugbank-id": "DB11616",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Pirarubicin"
                    },
                    {
                        "drugbank-id": "DB11693",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Voclosporin"
                    },
                    {
                        "drugbank-id": "DB11708",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Peficitinib"
                    },
                    {
                        "drugbank-id": "DB11767",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sarilumab"
                    },
                    {
                        "drugbank-id": "DB11776",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Brodalumab"
                    },
                    {
                        "drugbank-id": "DB11803",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sirukumab"
                    },
                    {
                        "drugbank-id": "DB11817",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Baricitinib"
                    },
                    {
                        "drugbank-id": "DB11834",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Guselkumab"
                    },
                    {
                        "drugbank-id": "DB11921",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Deflazacort"
                    },
                    {
                        "drugbank-id": "DB12025",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Triptolide"
                    },
                    {
                        "drugbank-id": "DB12371",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Siponimod"
                    },
                    {
                        "drugbank-id": "DB12612",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ozanimod"
                    },
                    {
                        "drugbank-id": "DB12617",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mizoribine"
                    },
                    {
                        "drugbank-id": "DB12692",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gusperimus"
                    },
                    {
                        "drugbank-id": "DB12814",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Cepeginterferon alfa 2B"
                    },
                    {
                        "drugbank-id": "DB12902",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Trofosfamide"
                    },
                    {
                        "drugbank-id": "DB12947",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Doxifluridine"
                    },
                    {
                        "drugbank-id": "DB12991",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Deoxyspergualin"
                    },
                    {
                        "drugbank-id": "DB12996",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Acteoside"
                    },
                    {
                        "drugbank-id": "DB13003",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Cortivazol"
                    },
                    {
                        "drugbank-id": "DB13014",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Hypericin"
                    },
                    {
                        "drugbank-id": "DB13068",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with 9 N methyl L isoleucine cyclosporin A"
                    },
                    {
                        "drugbank-id": "DB13208",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Prednylidene"
                    },
                    {
                        "drugbank-id": "DB13223",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fluocortin"
                    },
                    {
                        "drugbank-id": "DB13241",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Begelomab"
                    },
                    {
                        "drugbank-id": "DB13491",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fluperolone"
                    },
                    {
                        "drugbank-id": "DB13843",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Cloprednol"
                    },
                    {
                        "drugbank-id": "DB13856",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fluclorolone"
                    },
                    {
                        "drugbank-id": "DB13867",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fluticasone"
                    },
                    {
                        "drugbank-id": "DB14066",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tetrandrine"
                    },
                    {
                        "drugbank-id": "DB14219",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Monomethyl fumarate"
                    },
                    {
                        "drugbank-id": "DB14512",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mometasone furoate"
                    },
                    {
                        "drugbank-id": "DB14539",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Hydrocortisone acetate"
                    },
                    {
                        "drugbank-id": "DB14545",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Hydrocortisone succinate"
                    },
                    {
                        "drugbank-id": "DB14724",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Emapalumab"
                    },
                    {
                        "drugbank-id": "DB14762",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Risankizumab"
                    },
                    {
                        "drugbank-id": "DB14919",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Rozanolixizumab"
                    },
                    {
                        "drugbank-id": "DB15253",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bleselumab"
                    },
                    {
                        "drugbank-id": "DB01013",
                        "description": "The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01047",
                        "description": "The risk or severity of adverse effects can be increased when Fluocinonide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14540",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Hydrocortisone butyrate"
                    },
                    {
                        "drugbank-id": "DB00547",
                        "description": "The risk or severity of adverse effects can be increased when Desoximetasone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00764",
                        "description": "The risk or severity of adverse effects can be increased when Mometasone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08971",
                        "description": "The risk or severity of adverse effects can be increased when Fluocortolone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11750",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Clobetasol"
                    },
                    {
                        "drugbank-id": "DB00324",
                        "description": "The risk or severity of adverse effects can be increased when Fluorometholone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09095",
                        "description": "The risk or severity of adverse effects can be increased when Difluocortolone is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00108",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Natalizumab"
                    },
                    {
                        "drugbank-id": "DB00337",
                        "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01656",
                        "description": "Roflumilast may increase the immunosuppressive activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06688",
                        "description": "The therapeutic efficacy of Sipuleucel T can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00255",
                        "description": "Diethylstilbestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00269",
                        "description": "Chlorotrianisene may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00286",
                        "description": "Conjugated estrogens may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00655",
                        "description": "Estrone may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00783",
                        "description": "Estradiol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00890",
                        "description": "Dienestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00977",
                        "description": "Ethinylestradiol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01357",
                        "description": "Mestranol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04573",
                        "description": "Estriol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04574",
                        "description": "Estrone sulfate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04575",
                        "description": "Quinestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB07931",
                        "description": "Hexestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09070",
                        "description": "Tibolone may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09317",
                        "description": "Synthetic Conjugated Estrogens A may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09318",
                        "description": "Synthetic Conjugated Estrogens B may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09369",
                        "description": "Polyestradiol phosphate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09381",
                        "description": "Esterified estrogens may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11478",
                        "description": "Zeranol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11674",
                        "description": "Equol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB12487",
                        "description": "Promestriene may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13143",
                        "description": "Methallenestril may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13386",
                        "description": "Epimestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13418",
                        "description": "Moxestrol may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13952",
                        "description": "Estradiol acetate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13953",
                        "description": "Estradiol benzoate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13954",
                        "description": "Estradiol cypionate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13956",
                        "description": "Estradiol valerate may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15334",
                        "description": "Biochanin A may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15335",
                        "description": "Formononetin may increase the thrombogenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01097",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Leflunomide"
                    },
                    {
                        "drugbank-id": "DB08895",
                        "description": "Antilymphocyte immunoglobulin horse may increase the immunosuppressive activities of Tofacitinib"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08868",
                        "description": "Antilymphocyte immunoglobulin horse may increase the immunosuppressive activities of Fingolimod"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "Tacrolimus may increase the immunosuppressive activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04914",
                        "description": "The therapeutic efficacy of G17DT can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05144",
                        "description": "The therapeutic efficacy of PEV3A can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05325",
                        "description": "The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05374",
                        "description": "The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05440",
                        "description": "The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05942",
                        "description": "The therapeutic efficacy of GI 5005 can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06400",
                        "description": "The therapeutic efficacy of Vitespen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06584",
                        "description": "The therapeutic efficacy of TG4010 can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09057",
                        "description": "The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10062",
                        "description": "The therapeutic efficacy of Rabies virus inactivated antigen B can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10076",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10276",
                        "description": "The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10283",
                        "description": "The therapeutic efficacy of Rabies virus inactivated antigen A can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10342",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10583",
                        "description": "The therapeutic efficacy of Clostridium tetani toxoid antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10584",
                        "description": "The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10600",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 X 181 H1N1 antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10769",
                        "description": "The therapeutic efficacy of Japanese encephalitis virus strain sa 14 14 2 antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10794",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10803",
                        "description": "The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10989",
                        "description": "The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10990",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11038",
                        "description": "The therapeutic efficacy of Influenza A virus A Brisbane 59 2007 H1N1 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11040",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11041",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 X 181 H1N1 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11044",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11603",
                        "description": "The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11627",
                        "description": "The therapeutic efficacy of Hepatitis B Vaccine Recombinant can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB12568",
                        "description": "The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14022",
                        "description": "The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14384",
                        "description": "The therapeutic efficacy of Influenza A virus A Victoria 210 2009 X 187 H3N2 hemagglutinin antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14385",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 hemagglutinin antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14394",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 H1N1 live attenuated antigen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14445",
                        "description": "The therapeutic efficacy of Influenza A virus A Victoria 210 2009 X 187 H3N2 antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14449",
                        "description": "The therapeutic efficacy of Influenza A virus A Perth 16 2009 H3N2 live attenuated antigen can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14619",
                        "description": "The therapeutic efficacy of Influenza A virus A Uruguay 716 2007 H3N2 antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14620",
                        "description": "The therapeutic efficacy of Influenza A virus A Brisbane 59 2007 H1N1 antigen propiolactone inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14711",
                        "description": "The therapeutic efficacy of Smallpox Vaccinia Vaccine Live can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15274",
                        "description": "The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15461",
                        "description": "The therapeutic efficacy of Yersinia pestis 195 p antigen formaldehyde inactivated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB13924",
                        "description": "The therapeutic efficacy of Varicella Zoster Vaccine Recombinant can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15483",
                        "description": "The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15654",
                        "description": "The therapeutic efficacy of Moderna COVID 19 Vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11988",
                        "description": "Ocrelizumab may increase the immunosuppressive activities of Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10317",
                        "description": "The risk or severity of infection can be increased when Rubella virus vaccine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10318",
                        "description": "The risk or severity of infection can be increased when Varicella Zoster Vaccine Live attenuated is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10343",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain tice live antigen is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10804",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain connaught live antigen is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB10805",
                        "description": "The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11003",
                        "description": "The risk or severity of infection can be increased when Anthrax vaccine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB11050",
                        "description": "The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB12386",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain danish 1331 live antigen is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB12768",
                        "description": "The risk or severity of infection can be increased when BCG vaccine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14409",
                        "description": "The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl 68578 antigen is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The risk or severity of infection can be increased when Vibrio cholerae CVD 103 HgR strain live antigen is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14685",
                        "description": "The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00002",
                        "description": "The risk or severity of adverse effects can be increased when Cetuximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00028",
                        "description": "The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00043",
                        "description": "The risk or severity of adverse effects can be increased when Omalizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00054",
                        "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00057",
                        "description": "The risk or severity of adverse effects can be increased when Indium In 111 satumomab pendetide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00076",
                        "description": "The risk or severity of adverse effects can be increased when Digoxin Immune Fab Ovine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00089",
                        "description": "The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00110",
                        "description": "The risk or severity of adverse effects can be increased when Palivizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB00113",
                        "description": "The risk or severity of adverse effects can be increased when Technetium Tc 99m arcitumomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01269",
                        "description": "The risk or severity of adverse effects can be increased when Panitumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of adverse effects can be increased when Ranibizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04901",
                        "description": "The risk or severity of adverse effects can be increased when Galiximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04949",
                        "description": "The risk or severity of adverse effects can be increased when Pexelizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04958",
                        "description": "The risk or severity of adverse effects can be increased when Epratuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04962",
                        "description": "The risk or severity of adverse effects can be increased when Bectumomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04964",
                        "description": "The risk or severity of adverse effects can be increased when Oregovomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB04988",
                        "description": "The risk or severity of adverse effects can be increased when IGN311 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05006",
                        "description": "The risk or severity of adverse effects can be increased when Adecatumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05097",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05101",
                        "description": "The risk or severity of adverse effects can be increased when Matuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05111",
                        "description": "The risk or severity of adverse effects can be increased when Fontolizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05136",
                        "description": "The risk or severity of adverse effects can be increased when Bavituximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05139",
                        "description": "The risk or severity of adverse effects can be increased when CR002 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05209",
                        "description": "The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05304",
                        "description": "The risk or severity of adverse effects can be increased when Girentuximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05336",
                        "description": "The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05405",
                        "description": "The risk or severity of adverse effects can be increased when XTL 001 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05437",
                        "description": "The risk or severity of adverse effects can be increased when NAV 1800 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05496",
                        "description": "The risk or severity of adverse effects can be increased when Otelixizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05545",
                        "description": "The risk or severity of adverse effects can be increased when AMG 108 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05550",
                        "description": "The risk or severity of adverse effects can be increased when Iratumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05555",
                        "description": "The risk or severity of adverse effects can be increased when Enokizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05578",
                        "description": "The risk or severity of adverse effects can be increased when Ramucirumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05595",
                        "description": "The risk or severity of adverse effects can be increased when Farletuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05656",
                        "description": "The risk or severity of adverse effects can be increased when Veltuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05793",
                        "description": "The risk or severity of adverse effects can be increased when PRO 542 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05797",
                        "description": "The risk or severity of adverse effects can be increased when TNX 901 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05889",
                        "description": "The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05892",
                        "description": "The risk or severity of adverse effects can be increased when RI 624 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05915",
                        "description": "The risk or severity of adverse effects can be increased when MYO 029 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05916",
                        "description": "The risk or severity of adverse effects can be increased when CT 011 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05941",
                        "description": "The risk or severity of adverse effects can be increased when Leronlimab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB05996",
                        "description": "The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06043",
                        "description": "The risk or severity of adverse effects can be increased when Olaratumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06049",
                        "description": "The risk or severity of adverse effects can be increased when IPH 2101 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06050",
                        "description": "The risk or severity of adverse effects can be increased when TB 402 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06081",
                        "description": "The risk or severity of adverse effects can be increased when Caplacizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06101",
                        "description": "The risk or severity of adverse effects can be increased when IMC 1C11 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06116",
                        "description": "The risk or severity of adverse effects can be increased when Eldelumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06162",
                        "description": "The risk or severity of adverse effects can be increased when Lumiliximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06186",
                        "description": "The risk or severity of adverse effects can be increased when Ipilimumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06192",
                        "description": "The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06241",
                        "description": "The risk or severity of adverse effects can be increased when Clenoliximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06304",
                        "description": "The risk or severity of adverse effects can be increased when BIIB015 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06305",
                        "description": "The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06310",
                        "description": "The risk or severity of adverse effects can be increased when Motavizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06317",
                        "description": "The risk or severity of adverse effects can be increased when Elotuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06318",
                        "description": "The risk or severity of adverse effects can be increased when AVE9633 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06322",
                        "description": "The risk or severity of adverse effects can be increased when Carotuximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06324",
                        "description": "The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06342",
                        "description": "The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06343",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06360",
                        "description": "The risk or severity of adverse effects can be increased when Lucatumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06366",
                        "description": "The risk or severity of adverse effects can be increased when Pertuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06371",
                        "description": "The risk or severity of adverse effects can be increased when Siplizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06467",
                        "description": "The risk or severity of adverse effects can be increased when Apolizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06474",
                        "description": "The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06550",
                        "description": "The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06557",
                        "description": "The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06599",
                        "description": "The risk or severity of adverse effects can be increased when Lexatumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06602",
                        "description": "The risk or severity of adverse effects can be increased when Reslizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06606",
                        "description": "The risk or severity of adverse effects can be increased when Teplizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06607",
                        "description": "The risk or severity of adverse effects can be increased when Catumaxomab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of adverse effects can be increased when Volociximab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB06650",
                        "description": "The risk or severity of adverse effects can be increased when Ofatumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB08902",
                        "description": "The risk or severity of adverse effects can be increased when Raxibacumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09035",
                        "description": "The risk or severity of adverse effects can be increased when Nivolumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09037",
                        "description": "The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The risk or severity of adverse effects can be increased when Dulaglutide is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09105",
                        "description": "The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09264",
                        "description": "The risk or severity of adverse effects can be increased when Idarucizumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09302",
                        "description": "The risk or severity of adverse effects can be increased when Alirocumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09303",
                        "description": "The risk or severity of adverse effects can be increased when Evolocumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09331",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Daratumumab"
                    },
                    {
                        "drugbank-id": "DB09559",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Necitumumab"
                    },
                    {
                        "drugbank-id": "DB11595",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Atezolizumab"
                    },
                    {
                        "drugbank-id": "DB11604",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tetanus Immune Globulin"
                    },
                    {
                        "drugbank-id": "DB11608",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Eftrenonacog alfa"
                    },
                    {
                        "drugbank-id": "DB11621",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Human Varicella Zoster Immune Globulin"
                    },
                    {
                        "drugbank-id": "DB11646",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Conatumumab"
                    },
                    {
                        "drugbank-id": "DB11657",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tabalumab"
                    },
                    {
                        "drugbank-id": "DB11680",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ficlatuzumab"
                    },
                    {
                        "drugbank-id": "DB11685",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Figitumumab"
                    },
                    {
                        "drugbank-id": "DB11714",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Durvalumab"
                    },
                    {
                        "drugbank-id": "DB11715",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bapineuzumab"
                    },
                    {
                        "drugbank-id": "DB11731",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Depatuxizumab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11746",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Onartuzumab"
                    },
                    {
                        "drugbank-id": "DB11756",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Solanezumab"
                    },
                    {
                        "drugbank-id": "DB11771",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tremelimumab"
                    },
                    {
                        "drugbank-id": "DB11826",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lampalizumab"
                    },
                    {
                        "drugbank-id": "DB11840",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dalotuzumab"
                    },
                    {
                        "drugbank-id": "DB11849",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Emibetuzumab"
                    },
                    {
                        "drugbank-id": "DB11850",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ublituximab"
                    },
                    {
                        "drugbank-id": "DB11856",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ligelizumab"
                    },
                    {
                        "drugbank-id": "DB11857",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Seribantumab"
                    },
                    {
                        "drugbank-id": "DB11862",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Landogrozumab"
                    },
                    {
                        "drugbank-id": "DB11866",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Romosozumab"
                    },
                    {
                        "drugbank-id": "DB11884",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Vadastuximab Talirine"
                    },
                    {
                        "drugbank-id": "DB11914",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lebrikizumab"
                    },
                    {
                        "drugbank-id": "DB11930",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Varlilumab"
                    },
                    {
                        "drugbank-id": "DB11945",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Avelumab"
                    },
                    {
                        "drugbank-id": "DB11959",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Crenezumab"
                    },
                    {
                        "drugbank-id": "DB11972",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Rilotumumab"
                    },
                    {
                        "drugbank-id": "DB11976",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Anifrolumab"
                    },
                    {
                        "drugbank-id": "DB12023",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Benralizumab"
                    },
                    {
                        "drugbank-id": "DB12034",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gantenerumab"
                    },
                    {
                        "drugbank-id": "DB12053",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Visilizumab"
                    },
                    {
                        "drugbank-id": "DB12077",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Urelumab"
                    },
                    {
                        "drugbank-id": "DB12089",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lorvotuzumab mertansine"
                    },
                    {
                        "drugbank-id": "DB12090",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Patritumab"
                    },
                    {
                        "drugbank-id": "DB12102",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fulranumab"
                    },
                    {
                        "drugbank-id": "DB12104",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tarextumab"
                    },
                    {
                        "drugbank-id": "DB12118",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sotatercept"
                    },
                    {
                        "drugbank-id": "DB12119",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gevokizumab"
                    },
                    {
                        "drugbank-id": "DB12142",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Duligotuzumab"
                    },
                    {
                        "drugbank-id": "DB12152",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Simtuzumab"
                    },
                    {
                        "drugbank-id": "DB12157",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fasinumab"
                    },
                    {
                        "drugbank-id": "DB12159",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dupilumab"
                    },
                    {
                        "drugbank-id": "DB12169",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tralokinumab"
                    },
                    {
                        "drugbank-id": "DB12189",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Etrolizumab"
                    },
                    {
                        "drugbank-id": "DB12202",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Zalutumumab"
                    },
                    {
                        "drugbank-id": "DB12205",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ganitumab"
                    },
                    {
                        "drugbank-id": "DB12213",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Etaracizumab"
                    },
                    {
                        "drugbank-id": "DB12240",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Polatuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB12246",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Inclacumab"
                    },
                    {
                        "drugbank-id": "DB12250",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Cixutumumab"
                    },
                    {
                        "drugbank-id": "DB12261",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ascrinvacumab"
                    },
                    {
                        "drugbank-id": "DB12274",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Aducanumab"
                    },
                    {
                        "drugbank-id": "DB12281",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Luspatercept"
                    },
                    {
                        "drugbank-id": "DB12296",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with GS 5745"
                    },
                    {
                        "drugbank-id": "DB12317",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Vanucizumab"
                    },
                    {
                        "drugbank-id": "DB12331",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Labetuzumab govitecan"
                    },
                    {
                        "drugbank-id": "DB12335",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tanezumab"
                    },
                    {
                        "drugbank-id": "DB12342",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ensituximab"
                    },
                    {
                        "drugbank-id": "DB12344",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fezakinumab"
                    },
                    {
                        "drugbank-id": "DB12363",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dusigitumab"
                    },
                    {
                        "drugbank-id": "DB12396",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fresolimumab"
                    },
                    {
                        "drugbank-id": "DB12413",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Indusatumab vedotin"
                    },
                    {
                        "drugbank-id": "DB12456",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bococizumab"
                    },
                    {
                        "drugbank-id": "DB12489",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mirvetuximab Soravtansine"
                    },
                    {
                        "drugbank-id": "DB12498",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12520",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Plozalizumab"
                    },
                    {
                        "drugbank-id": "DB12534",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mavrilimumab"
                    },
                    {
                        "drugbank-id": "DB12560",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Blosozumab"
                    },
                    {
                        "drugbank-id": "DB12584",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bimagrumab"
                    },
                    {
                        "drugbank-id": "DB12589",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dacetuzumab"
                    },
                    {
                        "drugbank-id": "DB12609",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tovetumab"
                    },
                    {
                        "drugbank-id": "DB12683",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lumretuzumab"
                    },
                    {
                        "drugbank-id": "DB12698",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ibalizumab"
                    },
                    {
                        "drugbank-id": "DB12701",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Intetumumab"
                    },
                    {
                        "drugbank-id": "DB12718",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Carlumab"
                    },
                    {
                        "drugbank-id": "DB12734",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Demcizumab"
                    },
                    {
                        "drugbank-id": "DB12773",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sifalimumab"
                    },
                    {
                        "drugbank-id": "DB12775",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Abituzumab"
                    },
                    {
                        "drugbank-id": "DB12797",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ecromeximab"
                    },
                    {
                        "drugbank-id": "DB12807",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Naptumomab Estafenatox"
                    },
                    {
                        "drugbank-id": "DB12815",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Crotedumab"
                    },
                    {
                        "drugbank-id": "DB12820",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Concizumab"
                    },
                    {
                        "drugbank-id": "DB12826",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Depatuxizumab"
                    },
                    {
                        "drugbank-id": "DB12844",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Rontalizumab"
                    },
                    {
                        "drugbank-id": "DB12845",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Amatuximab"
                    },
                    {
                        "drugbank-id": "DB12849",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Clazakizumab"
                    },
                    {
                        "drugbank-id": "DB12891",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ozanezumab"
                    },
                    {
                        "drugbank-id": "DB12893",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sacituzumab govitecan"
                    },
                    {
                        "drugbank-id": "DB12917",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bimekizumab"
                    },
                    {
                        "drugbank-id": "DB12943",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Milatuzumab"
                    },
                    {
                        "drugbank-id": "DB12976",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Robatumumab"
                    },
                    {
                        "drugbank-id": "DB13017",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Rovalpituzumab Tesirine"
                    },
                    {
                        "drugbank-id": "DB13037",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Namilumab"
                    },
                    {
                        "drugbank-id": "DB13045",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Racotumomab"
                    },
                    {
                        "drugbank-id": "DB13073",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tregalizumab"
                    },
                    {
                        "drugbank-id": "DB13127",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Olokizumab"
                    },
                    {
                        "drugbank-id": "DB13140",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bezlotoxumab"
                    },
                    {
                        "drugbank-id": "DB13375",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Edrecolomab"
                    },
                    {
                        "drugbank-id": "DB13535",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Nebacumab"
                    },
                    {
                        "drugbank-id": "DB13886",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Human cytomegalovirus immune globulin"
                    },
                    {
                        "drugbank-id": "DB13923",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Emicizumab"
                    },
                    {
                        "drugbank-id": "DB13976",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sulesomab"
                    },
                    {
                        "drugbank-id": "DB13979",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Besilesomab"
                    },
                    {
                        "drugbank-id": "DB14012",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Burosumab"
                    },
                    {
                        "drugbank-id": "DB14039",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Erenumab"
                    },
                    {
                        "drugbank-id": "DB14040",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Eptinezumab"
                    },
                    {
                        "drugbank-id": "DB14041",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fremanezumab"
                    },
                    {
                        "drugbank-id": "DB14042",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Galcanezumab"
                    },
                    {
                        "drugbank-id": "DB14211",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Fanolesomab"
                    },
                    {
                        "drugbank-id": "DB14580",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lecanemab"
                    },
                    {
                        "drugbank-id": "DB14597",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lanadelumab"
                    },
                    {
                        "drugbank-id": "DB14707",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Cemiplimab"
                    },
                    {
                        "drugbank-id": "DB14776",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Camrelizumab"
                    },
                    {
                        "drugbank-id": "DB14778",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Setrusumab"
                    },
                    {
                        "drugbank-id": "DB14784",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gancotamab"
                    },
                    {
                        "drugbank-id": "DB14809",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Anetumab ravtansine"
                    },
                    {
                        "drugbank-id": "DB14811",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Isatuximab"
                    },
                    {
                        "drugbank-id": "DB14824",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Icrucumab"
                    },
                    {
                        "drugbank-id": "DB14843",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Codrituzumab"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Brolucizumab"
                    },
                    {
                        "drugbank-id": "DB14871",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Xentuzumab"
                    },
                    {
                        "drugbank-id": "DB14877",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lintuzumab"
                    },
                    {
                        "drugbank-id": "DB14891",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Vobarilizumab"
                    },
                    {
                        "drugbank-id": "DB14897",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Parsatuzumab"
                    },
                    {
                        "drugbank-id": "DB14905",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Emactuzumab"
                    },
                    {
                        "drugbank-id": "DB14907",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bevacizumab zirconium Zr 89"
                    },
                    {
                        "drugbank-id": "DB14908",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Refanezumab"
                    },
                    {
                        "drugbank-id": "DB14947",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Bermekimab"
                    },
                    {
                        "drugbank-id": "DB14952",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Pamrevlumab"
                    },
                    {
                        "drugbank-id": "DB14959",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Opicinumab"
                    },
                    {
                        "drugbank-id": "DB14962",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Trastuzumab deruxtecan"
                    },
                    {
                        "drugbank-id": "DB14967",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Margetuximab"
                    },
                    {
                        "drugbank-id": "DB14988",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Dalantercept"
                    },
                    {
                        "drugbank-id": "DB14997",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Pateclizumab"
                    },
                    {
                        "drugbank-id": "DB15014",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gremubamab"
                    },
                    {
                        "drugbank-id": "DB15022",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Apomab"
                    },
                    {
                        "drugbank-id": "DB15044",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tafasitamab"
                    },
                    {
                        "drugbank-id": "DB15045",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ipafricept"
                    },
                    {
                        "drugbank-id": "DB15076",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Abrilumab"
                    },
                    {
                        "drugbank-id": "DB15089",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Frovocimab"
                    },
                    {
                        "drugbank-id": "DB15090",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tezepelumab"
                    },
                    {
                        "drugbank-id": "DB15101",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tigatuzumab"
                    },
                    {
                        "drugbank-id": "DB15104",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Telisotuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15113",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Utomilumab"
                    },
                    {
                        "drugbank-id": "DB15118",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Zolbetuximab"
                    },
                    {
                        "drugbank-id": "DB15135",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ponezumab"
                    },
                    {
                        "drugbank-id": "DB15160",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Asunercept"
                    },
                    {
                        "drugbank-id": "DB15172",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Suvratoxumab"
                    },
                    {
                        "drugbank-id": "DB15225",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mitazalimab"
                    },
                    {
                        "drugbank-id": "DB15252",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Nemolizumab"
                    },
                    {
                        "drugbank-id": "DB15277",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Gedivumab"
                    },
                    {
                        "drugbank-id": "DB15336",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Valanafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15349",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Sofituzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15354",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Evinacumab"
                    },
                    {
                        "drugbank-id": "DB15363",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Istiratumab"
                    },
                    {
                        "drugbank-id": "DB15383",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Pidilizumab"
                    },
                    {
                        "drugbank-id": "DB15397",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with GMA 161"
                    },
                    {
                        "drugbank-id": "DB15409",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Ladiratuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15415",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tomaralimab"
                    },
                    {
                        "drugbank-id": "DB15428",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Vesencumab"
                    },
                    {
                        "drugbank-id": "DB15432",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Pinatuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15441",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lulizumab pegol"
                    },
                    {
                        "drugbank-id": "DB15443",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Lorukafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15453",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Naratuximab emtansine"
                    },
                    {
                        "drugbank-id": "DB14004",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Tildrakizumab"
                    },
                    {
                        "drugbank-id": "DB05679",
                        "description": "The risk or severity of adverse effects can be increased when Ustekinumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB15559",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Zenocutuzumab"
                    },
                    {
                        "drugbank-id": "DB15898",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Atoltivimab"
                    },
                    {
                        "drugbank-id": "DB15899",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Maftivimab"
                    },
                    {
                        "drugbank-id": "DB15900",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Odesivimab"
                    },
                    {
                        "drugbank-id": "DB15719",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00091",
                        "description": "Antilymphocyte immunoglobulin horse may increase the immunosuppressive activities of Cyclosporine"
                    },
                    {
                        "drugbank-id": "DB15595",
                        "description": "The therapeutic efficacy of Ebola Zaire vaccine live attenuated can be decreased when used in combination with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "The serum concentration of Magnesium can be decreased when it is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The serum concentration of Antilymphocyte immunoglobulin horse can be increased when it is combined with Lopinavir"
                    },
                    {
                        "drugbank-id": "DB12530",
                        "description": "The risk or severity of infection can be increased when Antilymphocyte immunoglobulin horse is combined with Inebilizumab"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}